Hostname: page-component-745bb68f8f-mzp66 Total loading time: 0 Render date: 2025-02-11T15:54:35.010Z Has data issue: false hasContentIssue false

Necrobiotic xanthogranuloma of the parotid gland

Published online by Cambridge University Press:  14 October 2009

A Zainal*
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
M Y Razif
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
M Makhashen
Affiliation:
Department of Pathology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
M Swaminathan
Affiliation:
Department of Pathology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
A Mazita
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
*
Address for correspondence: Dr A Zainal, Department of Otorhinolaryngology – Head and Neck Surgery, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur, Malaysia. Fax: 603 91737840 E-mail: azidazainal@gmail.com
Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To highlight the first reported case of necrobiotic xanthogranuloma of the parotid gland. We also review the clinical presentations and treatments for this rare condition.

Method:

Case report and review of necrobiotic xanthogranuloma.

Results:

A 48-year-old man presented with a right parotid mass. Fine needle aspiration cytology was suggestive of Warthin's tumour, for which the patient underwent a subtotal parotidectomy. The final histopathological diagnosis was necrobiotic xanthogranuloma.

Conclusions:

Necrobiotic xanthogranuloma may clinically mimic commoner tumours such as Warthin's tumour. Once diagnosed, the clinician should be wary of extracutaneous manifestations and paraproteinaemias. Because of the variability of presentation, there is no consensus on the best treatment for necrobiotic xanthogranuloma, which may include surgery, chemotherapy, interferon, plasmapheresis and radiation therapy.

Type
Clinical Records
Copyright
Copyright © JLO (1984) Limited 2009

Introduction

Necrobiotic xanthogranuloma is a rare, progressive, histiocytic disease. Although it commonly involves cutaneous sites around the periorbital region, it is now considered a systemic disease which can involve the myocardium, larynx, pharynx, lungs, intestines and ovaries.Reference Finan and Winklemann1

We report the first case of necrobiotic xanthogranuloma of the parotid gland, which was diagnosed histopathologically following a subtotal parotidectomy in a 48-year-old man.

Case report

A 48-year-old Malay man presented with a four-year history of a right parotid mass which had been gradually increasing in size. There was one episode of pain, one month prior to the current presentation, which was treated by his general practitioner as acute infection. This episode was not related to meals and was not associated with any constitutional symptoms.

The patient had no known medical problems, and was found to have Type 2 diabetes mellitus only on routine blood glucose testing. Systems enquiry was unremarkable.

On examination, a firm, non-tender, mobile, 6×6 cm mass was palpable at the right angle of the mandible. There was no inflammation of Stensen's duct or any medialisation of the right lateral pharyngeal wall. Right facial nerve function was intact. The patient did not have any periorbital or subcutaneous lesions elsewhere on his body.

Fine needle aspiration cytology (FNAC) analysis of the right parotid mass revealed features consistent with Warthin's tumour.

Three months later, the patient underwent a right subtotal parotidectomy. (There had been no physical change in the mass between FNAC and surgery.)

Intra-operatively, a well-encapsulated mass was identified at the tail of the right parotid gland, extending into the deep lobe. Examination of the specimen revealed a cystic, 2.5×2.5×3 cm lesion within the right parotid gland filled with yellowish, fragile, necrotic tissue.

Microscopic examination showed sections of cystic tissue filled with necrotic material and infiltrated with chronic inflammatory cells. Numerous large foamy macrophages (Figure 1), multinucleated giant cells (Figure 2) of the Touton and foreign body-types, and cholesterol clefts (Figure 3) could be seen in a background of extensive tissue necrosis. Normal salivary gland tissue and some lymphoid aggregates were seen at the surrounding areas. There was no evidence of caseating necrosis, epithelioid granuloma or Langhans giant cells. No organisms were demonstrated on Ziehl–Neelson, periodic acid Schiff, Grocott and Giemsa staining. These features were consistent with necrobiotic xanthogranuloma. There were no histological features of the specimen suggestive of Warthin's tumour.

Fig. 1 Photomicrograph of surgical specimen showing large, foamy macrophages (arrowheads) (H&E; ×20).

Fig. 2 Photomicrograph of surgical specimen showing multinucleated giant cells (arrowheads) (H&E; ×20).

Fig. 3 Photomicrograph of surgical specimen showing cholesterol clefts (arrowheads) (H&E; ×20).

Post-operatively, the patient recovered well without complication. After eight months of follow up, the patient remained well with no constitutional symptoms.

Discussion

Necrobiotic xanthogranuloma is a rare, progressive, histiocytic disease. In the World Health Organization ICD-10 classification of diseases, it falls within the category of ‘other histiocytosis syndromes’ (category D76.3). In the Medical Subject Heading classification system, it is grouped under non-Langerhans cell histiocytosis. In 1987, histiocytic disorders were classified into three categories by the Histiocyte Society Writing Group: class I (Langerhans cell histiocytosis–histiocytosis X spectrum); class II (histiocytosis of mononuclear phagocytes other than Langerhans cells); and class III (malignant histiocytic disorders).Reference Moschella2 Adult xanthogranulomatous disease falls within class II of this categorisation. It is a disease of unknown aetiology characterised by variable involvement of a spectrum of symptoms, including destructive periorbital and cutaneous lesions, multiple extracutaneous manifestations, and paraproteinaemias. The mean age of onset is the sixth decade and there is no sex predilection.Reference Mehregan and Winklemann3

In 2006, Sivak-Callcott et al. organised a multi-institutional effort to study adult xanthogranulomata, and were able to categorise it into four syndromes based on histopathological, immunohistochemical, clinical and systemic features, as follows: (1) adult onset xanthogranuloma (solitary lesion without systemic findings); (2) adult onset asthma and periocular xanthogranuloma; (3) necrobiotic xanthogranuloma; and (4) Erdheim–Chester disease.Reference Sivak-Callcott, Rootman, Rasmussen, Nugent, White and Paridaens4

Necrobiotic xanthogranuloma is characterised by the presence of multiple, indurate, yellow-red plaques in the head and neck area (especially the periorbital region) and trunk; however, although characteristic, such lesions are not necessary for diagnosis.Reference Chave and Hutchinson5

Eighty per cent of necrobiotic xanthogranuloma cases have been associated with paraproteinaemia; the most common type is immunoglobulin (Ig) Gκ monoclonal gammopathy (60 per cent), followed by IgGλ (26 per cent) and IgA.Reference Finan and Winklemann1, Reference Martinez Fernandez, Rodriguez Prieto, Ruiz Gonzalez, Sanchez Sambucety and Delgado Vicente6 In 10 per cent of cases, the monoclonal gammopathy develops into multiple myeloma.Reference Martinez Fernandez, Rodriguez Prieto, Ruiz Gonzalez, Sanchez Sambucety and Delgado Vicente6

A review of necrobiotic xanthogranuloma by Finan and Winklemann revealed the involvement of extracutaneous sites such as the spleen, lung, kidney, intestine, ovary, skeletal muscle and central nervous system.Reference Finan and Winklemann1 The larynx and pharynx are the only sites within the head and neck region reported to be involved with necrobiotic xanthogranuloma.

Necrobiotic xanthogranuloma can be histologically characterised by: xanthomatised histiocytes; giant, bizarre foreign body cells; Touton cells; lymphocyte aggregates; cholesterol clefts; and areas of severe necrobiosis.Reference Finan and Winkelmann7

Because of the rarity of this disease, the outcome of therapy is difficult to evaluate, as multiple therapeutic modalities have been used in all the syndromes, including chemotherapy, interferon (α-2b or α-2a), plasmapheresis, intralesional steroid injections, cryotherapy, radiation therapy and surgery.Reference Finan and Winkelmann7Reference Elner, Mintz, Demirci and Hassan13 The best results have been obtained with multiagent chemotherapy, with or without radiation or surgery.Reference Sivak-Callcott, Rootman, Rasmussen, Nugent, White and Paridaens4 Sivak-Callcott et al. also recommend characterisation of histiocytes and correlation with histopathological B and T cell findings, when choosing an immunosuppressive agent for treatment.Reference Sivak-Callcott, Rootman, Rasmussen, Nugent, White and Paridaens4

To our knowledge, the current patient represents the first reported case of necrobiotic xanthogranuloma of the parotid gland. This is a different histological entity to xanthogranulomatous sialadenitis, a handful of cases of which have been reported.Reference Cocco, MacLennan, Lavertu and Wasman14

  • Necrobiotic xanthogranuloma is a rare, progressive, histiocytic disease

  • It is a systemic disease which may involve cutaneous and extracutaneous sites, and which is associated with paraproteinaemias

  • Necrobiotic xanthogranuloma may present as a swelling of the parotid gland

  • For an isolated swelling, surgical excision is a reasonable management option

In our patient, the diagnosis was made from the classical histological features of necrobiotic xanthogranuloma. Because the lesion was removed in its entirety during the subtotal parotidectomy, and the patient did not show any manifestation of cutaneous or systemic necrobiotic xanthogranuloma, the decision was made to follow him up expectantly.

References

1Finan, MC, Winklemann, RK. Necrobiotic xanthogranuloma with paraproteinaemia. A review of 22 cases. Medicine 1986;65:376–88CrossRefGoogle Scholar
2Moschella, SL. An update of the benign proliferative monocyte-macrophage and dendritic cell disorders. J Dermatol 1996;23:805–15CrossRefGoogle ScholarPubMed
3Mehregan, DA, Winklemann, RK. Necrobiotic xanthogranuloma. Arch Dermatol 1992;128:94100CrossRefGoogle ScholarPubMed
4Sivak-Callcott, JA, Rootman, J, Rasmussen, SL, Nugent, RA, White, VA, Paridaens, D et al. Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review. Br J Ophthalmol 2006;90:602–8CrossRefGoogle ScholarPubMed
5Chave, TA, Hutchinson, PE. Necrobiotic xanthogranuloma with two monoclonal paraproteins and no periorbital involvement at presentation. Clin Exp Dermatol 2001;26:493–6CrossRefGoogle ScholarPubMed
6Martinez Fernandez, M, Rodriguez Prieto, MA, Ruiz Gonzalez, I, Sanchez Sambucety, P, Delgado Vicente, S. Necrobiotic xanthogranuloma associated with myeloma. J Eur Acad Dermatol Venereol 2004;18:328–31CrossRefGoogle ScholarPubMed
7Finan, MC, Winkelmann, RK. Histopathology of necrobiotic xanthogranuloma with paraproteinaemia. J Cutan Pathol 1987;14:92–9CrossRefGoogle Scholar
8Machado, S, Alves, R, Lima, M, Leal, I, Massa, A. Cutaneous necrobiotic xanthogranuloma (NXG) successfully treated with low dose chlorambucil. Eur J Dermatol 2001;11:458–62Google ScholarPubMed
9Meyer, S, Szeimies, RM, Landthaler, M, Hohenleutner, S. Cyclophosphamide-dexamethasone pulsed therapy for treatment of recalcitrant necrobiotic xanthogranuloma with paraproteinaemia and ocular involvement. Br J Dermatol 2005;153:443–5CrossRefGoogle ScholarPubMed
10Venencie, PY, Le Bras, P, Toan, ND, Tchernia, G, Delfraissy, JF. Recombinant interferon alfa-2b treatment of necrobiotic xanthogranuloma with paraproteinaemia. J Am Acad Dermatol 1995;32:666–7CrossRefGoogle Scholar
11Georgiou, S, Monastirli, A, Kapranos, N, Pasmatzi, E, Sakkis, T, Tsambaos, D. Interferon alpha-2a monotherapy for necrobiotic xanthogranuloma. Acta Derm Venereol 1999;24:484–9CrossRefGoogle Scholar
12Finelli, LG, Ratz, JL. Plasmapheresis: a treatment modality for necrobiotic xanthogranuloma. J Am Acad Dermatol 1987;17:351–4CrossRefGoogle ScholarPubMed
13Elner, VM, Mintz, R, Demirci, H, Hassan, AS. Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Ophthal Plast Reconstr Surg 2006;22:3640CrossRefGoogle ScholarPubMed
14Cocco, AE, MacLennan, GT, Lavertu, P, Wasman, JK. Xanthogranulomatous sialadenitis: a case report and literature review. Ear Nose Throat J 2005;84:369–70CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1 Photomicrograph of surgical specimen showing large, foamy macrophages (arrowheads) (H&E; ×20).

Figure 1

Fig. 2 Photomicrograph of surgical specimen showing multinucleated giant cells (arrowheads) (H&E; ×20).

Figure 2

Fig. 3 Photomicrograph of surgical specimen showing cholesterol clefts (arrowheads) (H&E; ×20).